Literature DB >> 9365880

Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.

J T Bryan1, K U Jansen, R S Lowe, K H Fife, T McClowry, D Glass, D R Brown.   

Abstract

Neutralization of virus is likely to be necessary for development of an effective prophylactic vaccine against genital human papillomavirus (HPV) infection. Two New Zealand white rabbits were immunized with purified HPV type 11 (HPV 11) virions in Freund's adjuvant. An enzyme linked immunoassay (ELISA) was used to determine the quantity of IgG which recognized the HPV 11 major capsid protein (L1 protein) virus-like particles (VLPs) in the two anti-HPV 11 sera (serum A and serum B). The concentration of HPV 11 L1 VLP-specific IgG in the A and B sera were determined to be 37 and 90 micrograms per ml, respectively. The A and B sera were used in neutralization experiments in the athymic mouse xenograft system with known quantities of purified HPV 11 virions. The concentration of HPV 11 L1 VLP-specific IgG required to neutralize HPV 11 was determined for each antiserum. This concentration of IgG was approximately 700 to 900 ng per ml. This study demonstrates a positive correlation between the level of HPV 11 L1 VLP-specific IgG in animals immunized with HPV 11 virions and neutralization of HPV 11 in the athymic mouse model. Further studies are needed 1) to determine if sera or genital secretions from other species are neutralizing in the athymic mouse xenograft system, and 2) to determine if the VLP ELISA can be used as a reliable substitute for more cumbersome neutralization assays.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365880     DOI: 10.1002/(sici)1096-9071(199711)53:3<185::aid-jmv1>3.0.co;2-4

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination.

Authors:  K Eriksson; M Quiding-Järbrink; J Osek; A Möller; S Björk; J Holmgren; C Czerkinsky
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

3.  Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.

Authors:  Tino F Schwarz; Marek Spaczynski; Achim Schneider; Jacek Wysocki; Andrzej Galaj; Karin Schulze; Sylviane M Poncelet; Gregory Catteau; Florence Thomas; Dominique Descamps
Journal:  Hum Vaccin       Date:  2011-09-01

Review 4.  Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

Authors:  Christine Roberts; Tina Green; Erica Hess; Katie Matys; Martha J Brown; Richard M Haupt; Alain Luxembourg; Scott Vuocolo; Alfred Saah; Joseph Antonello
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Authors:  C Balmelli; R Roden; A Potts; J Schiller; P De Grandi; D Nardelli-Haefliger
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.

Authors:  David Opalka; Charles E Lachman; Stefani A MacMullen; Kathrin U Jansen; Judith F Smith; Narendra Chirmule; Mark T Esser
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

7.  Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

Authors:  S Gerber; C Lane; D M Brown; E Lord; M DiLorenzo; J D Clements; E Rybicki; A L Williamson; R C Rose
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant.

Authors:  Wanda Ruiz; William L McClements; Kathrin U Jansen; Mark T Esser
Journal:  J Immune Based Ther Vaccines       Date:  2005-04-20

Review 9.  Current view on novel vaccine technologies to combat human infectious diseases.

Authors:  Zrinka Matić; Maja Šantak
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-10       Impact factor: 4.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.